Post by icemandios on Mar 11, 2021 14:06:31 GMT
Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting
PR Newswire
MARLBOROUGH, Mass. , March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it will present new study data regarding the direct drug application of its product candidate, PH-762, at the AACR Annual Meeting 2021. The AACR 2021 meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Presentation details:
Title:
Intratumoral INTASYL™ self-delivering RNAi targeting PD-1 provides in vivo tumor control and mechanistic modulation of tumor microenvironment analogous to that of systemic anti-PD-1 antibody
Authors: Benjamin Cuiffo, et al .
Session Title: Immunomodulatory Agents and Interventions
Abstract Number: 1739
The poster presentation will be made available on the " Investors – Events and Presentations " section of the Company's website.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , March 11, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced it will present new study data regarding the direct drug application of its product candidate, PH-762, at the AACR Annual Meeting 2021. The AACR 2021 meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Presentation details:
Title:
Intratumoral INTASYL™ self-delivering RNAi targeting PD-1 provides in vivo tumor control and mechanistic modulation of tumor microenvironment analogous to that of systemic anti-PD-1 antibody
Authors: Benjamin Cuiffo, et al .
Session Title: Immunomodulatory Agents and Interventions
Abstract Number: 1739
The poster presentation will be made available on the " Investors – Events and Presentations " section of the Company's website.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .